Form 4: CVS Health Director Anne A. Finucane Reports Acquisition of Deferred Stock Units

Director Anne A. Finucane acquired 2,200.0876 deferred stock units of CVS Health, increasing her indirect holdings.

Summary

• Anne A. Finucane, a director at CVS Health, reported a transaction involving deferred stock units.
• On November 21, 2024, she acquired 2,200.0876 deferred stock units.
• These units were issued as part of her semi-annual retainer under the company's non-employee director compensation policy.
• The deferred stock units are valued at the market price and will be converted into common stock in the future, as elected by Ms. Finucane.
• Following this transaction, Ms. Finucane directly owns 7,232.2482 shares of common stock and indirectly owns 25,198 shares through the Finucane Family Trust.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of insider transactions, which is generally neutral. The acquisition of stock units by a director can be seen as a positive sign of confidence in the company, but it's a standard part of compensation.

Positives

• The acquisition of deferred stock units aligns the director's interests with the company's performance.
• The transaction reflects the company's commitment to its non-employee director compensation policy.

Future Outlook

The deferred stock units will be converted into common stock at a future date, as elected by the reporting person.

Industry Context

This filing is a routine disclosure of insider transactions, which is common for publicly traded companies like CVS Health. It provides transparency into the holdings of company directors.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and CVS Health's filing is consistent with these requirements.
• Other companies such as Walgreens Boots Alliance (WBA) and UnitedHealth Group (UNH) also have similar filings when their directors or officers trade company stock.
• The use of deferred stock units as part of director compensation is a common practice among large corporations.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns director interests with company performance.

Key Dates

Keywords

CVS Health, deferred stock units, director, insider trading, Form 4, Anne A. Finucane, executive compensation